UNION KOREA PHARM CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,190 KRW | +1.81% |
|
-0.48% | +25.05% |
| Sales 2022 | 61.29B 44.93M 61.54M | Sales 2023 | 63.17B 46.3M 63.42M | Capitalization | 35.74B 26.2M 35.88M |
|---|---|---|---|---|---|
| Net income 2022 | -932M -683K -936K | Net income 2023 | -18.16B -13.31M -18.23M | EV / Sales 2022 | 1.33 x |
| Net Debt 2022 | 29.6B 21.7M 29.72M | Net Debt 2023 | 32.17B 23.58M 32.3M | EV / Sales 2023 | 1.08 x |
| P/E ratio 2022 |
-56.6
x | P/E ratio 2023 |
-1.97
x | Employees | 203 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 60.59% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.81% | ||
| 1 week | -0.48% | ||
| Current month | +1.64% | ||
| 1 month | +4.92% | ||
| 3 months | +14.00% | ||
| 6 months | +34.57% | ||
| Current year | +25.05% |
1 week
6 070.00
6 440.00
1 month
5 750.006 440.00
Current year
4 450.006 460.00
1 year
4 210.006 460.00
3 years
4 210.0016 400.00
5 years
4 210.0027 450.00
10 years
4 210.0027 450.00
| Managers | Title | Age | Since |
|---|---|---|---|
Byeong-Ha Baek
CEO | Chief Executive Officer | 67 | 01-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Byeong-Ha Baek
CEO | Chief Executive Officer | 67 | 01-02-28 |
Jung-Hyun Park
BRD | Director/Board Member | 47 | 20-03-23 |
Young-Gon Cho
BRD | Director/Board Member | 62 | 22-03-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-22 | 6,190 | +1.81% | 12,189 |
| 24-05-21 | 6,080 | -5.30% | 19,794 |
| 24-05-20 | 6,420 | +1.58% | 27,110 |
| 24-05-17 | 6,320 | +0.96% | 19,239 |
| 24-05-16 | 6,260 | +0.64% | 14,353 |
End-of-day quote Korea S.E., May 21, 2024
More quotes
UNION KOREA PHARM CO.LTD. is a Korea-based company mainly engaged in the manufacturing and distribution of pharmaceuticals. The Company manufactures and sells specialty medicines through formulations such as solid dosage forms, liquid injections, and cefa powder injections. Major products include antibiotics such as kepodon injection and ceftazime injection 1g for the prevention and treatment of infectious diseases; musculoskeletal drugs for treating arthritis contains unihyal injection and galithio injection; circulatory system dugs for the treatment of cerebrovascular diseases, such as cacetile tab and limasta tab; as well as drugs for digestive system such as digestive disorders. In addition, the Company engaged in the contract manufacturing operation (CMO) business for other pharmaceutical companies. The Company distributes its products within domestic market and to overseas markets including Middle East, Southeast Asia and Latin America.
Sector
Pharmaceuticals
Calendar
2024-08-13
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +25.05% | 32.23M | |
| +16.93% | 78.22B | |
| +9.16% | 8.84B | |
| -14.24% | 5.07B | |
| +49.95% | 4.82B | |
| +5.96% | 4.2B | |
| +11.81% | 2.28B | |
| -23.57% | 2.28B | |
| +17.77% | 2.2B | |
| -32.28% | 2.12B |
- Stock Market
- Equities
- A080720 Stock
